Kenneth D R Setchell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1986799/publications.pdf

Version: 2024-02-01

141 papers

13,760 citations

51
h-index

20961 115 g-index

142 all docs

142 docs citations

times ranked

142

10213 citing authors

#	Article	IF	CITATIONS
1	Testâ€dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for nonâ€malignant disorders. British Journal of Clinical Pharmacology, 2022, 88, 115-127.	2.4	5
2	Cutting Edge: <scp>l</scp> -Arginine Transfer from Antigen-Presenting Cells Sustains CD4+ T Cell Viability and Proliferation. Journal of Immunology, 2022, 208, 793-798.	0.8	3
3	Rates of substance and polysubstance use through universal maternal testing at the time of delivery. Journal of Perinatology, 2022, 42, 1026-1031.	2.0	10
4	Maralixibat for the treatment of PFIC: Longâ€term, IBAT inhibition in an openâ€label, Phase 2 study. Hepatology Communications, 2022, 6, 2379-2390.	4.3	26
5	Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice. Mucosal Immunology, 2021, 14, 500-510.	6.0	21
6	Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan. journal of applied laboratory medicine, The, 2021, 6, 625-636.	1.3	5
7	Modeling Human Bile Acid Transport and Synthesis in Stem Cell-Derived Hepatocytes with a Patient-Specific Mutation. Stem Cell Reports, 2021, 16, 309-323.	4.8	3
8	Regional comparison of self-reported late pregnancy cigarette smoking to mass spectrometry analysis. Journal of Perinatology, 2021, 41, 2417-2423.	2.0	3
9	Successful treatment of infantile oxysterol 7α-hydroxylase deficiency with oral chenodeoxycholic acid. BMC Gastroenterology, 2021, 21, 163.	2.0	4
10	Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease. Cells, 2021, 10, 2286.	4.1	10
11	Bile Acid Profiling Reveals Distinct Signatures in Undernourished Children with Environmental Enteric Dysfunction. Journal of Nutrition, 2021, 151, 3689-3700.	2.9	13
12	Genetic spectrum and clinical characteristics of 31 ² -hydroxy-1"5-C27-steroid oxidoreductase (HSD3B7) deficiency in China. Orphanet Journal of Rare Diseases, 2021, 16, 417.	2.7	4
13	Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet, The, 2021, 398, 1581-1592.	13.7	77
14	Electronic Health Record–Embedded Decision Support Platform for Morphine Precision Dosing in Neonates. Clinical Pharmacology and Therapeutics, 2020, 107, 186-194.	4.7	33
15	Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity. Journal of Cystic Fibrosis, 2020, 19, 632-640.	0.7	10
16	Improving natural product research translation: From source to clinical trial. FASEB Journal, 2020, 34, 41-65.	0.5	45
17	Inhibition of Cdc42 activity extends lifespan and decreases circulating inflammatory cytokines in aged female C57BL/6 mice. Aging Cell, 2020, 19, e13208.	6.7	31
18	Abnormal Bilirubin Metabolism in Patients With Sodium Taurocholate Cotransporting Polypeptide Deficiency. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, e138-e141.	1.8	9

#	Article	IF	CITATIONS
19	Model-Informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants. Therapeutic Drug Monitoring, 2020, 42, 778-786.	2.0	10
20	Assessment of the role of FGF15 in mediating the metabolic outcomes of murine vertical sleeve gastrectomy. American Journal of Physiology - Renal Physiology, 2020, 319, G669-G684.	3.4	9
21	Openâ€label Phase 3 Continuation Study of Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, 423-429.	1.8	12
22	Analysis of chlorhexidine gluconate in skin using tape stripping and ultrahigh-performance liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2020, 183, 113111.	2.8	5
23	Study of Environmental Enteropathy and Malnutrition (SEEM) in Pakistan: protocols for biopsy based biomarker discovery and validation. BMC Pediatrics, 2019, 19, 247.	1.7	22
24	<scp> </scp> -Arginine Synthesis from <scp> </scp> -Citrulline in Myeloid Cells Drives Host Defense against Mycobacteria In Vivo. Journal of Immunology, 2019, 202, 1747-1754.	0.8	29
25	Data analysis of MS-based clinical lipidomics studies with crossover design: A tutorial mini-review of statistical methods. Clinical Mass Spectrometry, 2019, 13, 5-17.	1.9	11
26	The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear \hat{l}^2 -Catenin. Molecular Cancer Therapeutics, 2019, 18, 1217-1229.	4.1	42
27	Analysis of the MILES cohort reveals determinants of disease progression andÂtreatment response in lymphangioleiomyomatosis. European Respiratory Journal, 2019, 53, 1802066.	6.7	41
28	Combination of acid \hat{l}^2 -glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype. Scientific Reports, 2019, 9, 5571.	3.3	17
29	Bile Acid Synthesis Disorder Masquerading as Intractable Vitamin D-Deficiency Rickets. Journal of the Endocrine Society, 2019, 3, 397-402.	0.2	7
30	Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization. Leukemia, 2019, 33, 749-761.	7.2	48
31	Effect of bariatric surgery on urinary sphingolipids in adolescents with severe obesity. Surgery for Obesity and Related Diseases, 2018, 14, 446-451.	1.2	9
32	Lipidomic Profiling Links the Fanconi Anemia Pathway to Glycosphingolipid Metabolism in Head and Neck Cancer Cells. Clinical Cancer Research, 2018, 24, 2700-2709.	7.0	21
33	Oral Cholic Acid Is Efficacious and Well Tolerated in Patients With Bile Acid Synthesis and Zellweger Spectrum Disorders. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, e57-e59.	1.8	5
34	Inborn Errors of Bile Acid Metabolism. Clinics in Liver Disease, 2018, 22, 671-687.	2.1	42
35	Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease. Journal of Molecular Medicine, 2018, 96, 1359-1373.	3.9	34
36	Long-Term Cholic Acid Therapy in Zellweger Spectrum Disorders. Case Reports in Gastroenterology, 2018, 12, 360-372.	0.6	9

#	Article	IF	Citations
37	Plasma glucosylceramides and cardiovascular risk in incident hemodialysis patients. Journal of Clinical Lipidology, 2018, 12, 1513-1522.e4.	1.5	10
38	Will the real bile acid sulfotransferase please stand up? Identification of Sult2a8 as a major hepatic bile acid sulfonating enzyme in mice. Journal of Lipid Research, 2017, 58, 1033-1035.	4.2	14
39	Test Dose Pharmacokinetics to Predict Melphalan Dosing in Children Undergoing Hematopoietic Stem Cell Transplant (HSCT) with Organ Impairmentâ †. Biology of Blood and Marrow Transplantation, 2017, 23, S228.	2.0	2
40	Hepatic MDR3 expression impacts lipid homeostasis and susceptibility to inflammatory bile duct obstruction in neonates. Pediatric Research, 2017, 82, 122-132.	2.3	6
41	Severe Neonatal Cholestasis in Cerebrotendinous Xanthomatosis. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 561-568.	1.8	27
42	Bile Acid Synthesis Disorders in Arabs: A 10-year Screening Study. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 613-620.	1.8	16
43	Tissue Localization of Glycosphingolipid Accumulation in a Gaucher Disease Mouse Brain by LC-ESI-MS/MS and High-Resolution MALDI Imaging Mass Spectrometry. SLAS Discovery, 2017, 22, 1218-1228.	2.7	28
44	A convenient approach to facilitate monitoring Gaucher disease progression and therapeutic response. Analyst, The, 2017, 142, 3380-3387.	3.5	13
45	The history and basic science development of soy isoflavones. Menopause, 2017, 24, 1338-1350.	2.0	37
46	Oral Cholic Acid Is Efficacious and Well Tolerated in Patients With Bile Acid Synthesis and Zellweger Spectrum Disorders. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 321-326.	1.8	36
47	Stable-Isotope Dilution HPLC–Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples. Clinical Chemistry, 2016, 62, 1593-1601.	3.2	31
48	Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice. Human Molecular Genetics, 2016, 25, ddw322.	2.9	30
49	Fibroblast growth factor 21 correlates with weight loss after vertical sleeve gastrectomy in adolescents. Obesity, 2016, 24, 2377-2383.	3.0	33
50	Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice. Science Translational Medicine, 2016, 8, 357ra122.	12.4	160
51	Progranulin Recruits HSP70 to \hat{l}^2 -Glucocerebrosidase and Is Therapeutic Against Gaucher Disease. EBioMedicine, 2016, 13, 212-224.	6.1	88
52	Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease. Journal of Pediatrics, 2016, 177, 59-65.e1.	1.8	20
53	Pharmacological inhibition of apical sodiumâ€dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology, 2016, 63, 512-523.	7.3	113
54	Distinct urinary lipid profile in children with focal segmental glomerulosclerosis. Pediatric Nephrology, 2016, 31, 581-588.	1.7	16

#	Article	IF	CITATIONS
55	Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 1009-1019.	2.6	74
56	Let the bile flow!. Hepatology, 2015, 62, 1870-1870.	7.3	2
57	S-equol: A Potential Nonhormonal Agent for Menopause-Related Symptom Relief. Journal of Women's Health, 2015, 24, 200-208.	3.3	27
58	Tandem Mass Spectrometric Determination of Atypical 3Î ² -Hydroxy-Δ5-Bile Acids in Patients with 3Î ² -Hydroxy-Δ5-C27-Steroid Oxidoreductase Deficiency: Application to Diagnosis and Monitoring of Bile Acid Therapeutic Response. Clinical Chemistry, 2015, 61, 955-963.	3.2	15
59	CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11years of therapy: Clinical, histopathologic, and biochemical findings. Molecular Genetics and Metabolism, 2015, 114, 233-241.	1.1	54
60	Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model. Human Molecular Genetics, 2015, 24, ddv404.	2.9	36
61	Differential Requirements for <scp>l</scp> -Citrulline and <scp>l</scp> -Arginine during Antimycobacterial Macrophage Activity. Journal of Immunology, 2015, 195, 3293-3300.	0.8	39
62	Vitamin D Deficiency and Survival in Children after Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, 1627-1631.	2.0	59
63	Treatment of bile acid amidation defects with glycocholic acid. Hepatology, 2015, 61, 268-274.	7.3	47
64	Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology. PLoS ONE, 2015, 10, e0118771.	2.5	39
65	Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model. PLoS ONE, 2014, 9, e116023.	2.5	10
66	Disorders of bile acid synthesis and metabolism. , 2014, , 567-586.		4
67	Gaucher disease: Chemotactic factors and immunological cell invasion in a mouse model. Molecular Genetics and Metabolism, 2014, 111, 163-171.	1.1	28
68	Metabolism of secoisolariciresinol-diglycoside the dietary precursor to the intestinally derived lignan enterolactone in humans. Food and Function, 2014, 5, 491-501.	4.6	64
69	Synthesis of atypical bile acids for use as investigative tools for the genetic defect of 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 348-360.	2.5	10
70	The tumour suppressor LKB1 regulates myelination through mitochondrial metabolism. Nature Communications, 2014, 5, 4993.	12.8	61
71	S-(\hat{a} °)equol production is developmentally regulated and related to early diet composition. Nutrition Research, 2014, 34, 401-409.	2.9	24
72	Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Human Molecular Genetics, 2014, 23, 3943-3957.	2.9	79

#	Article	IF	Citations
73	Genetic Defects in Bile Acid Conjugation Cause Fat-Soluble Vitamin Deficiency. Gastroenterology, 2013, 144, 945-955.e6.	1.3	97
74	Dietary Factors Influence Production of the Soy Isoflavone Metabolite S-(-)Equol in Healthy Adults. Journal of Nutrition, 2013, 143, 1950-1958.	2.9	52
75	Cross-Border Use of Food Databases: Equivalence of US and Australian Databases for Macronutrients. Journal of the Academy of Nutrition and Dietetics, 2013, 113, 1340-1345.	0.8	8
76	Novel Soy Germ Pasta Enriched in Isoflavones Ameliorates Gastroparesis in Type 2 Diabetes. Diabetes Care, 2013, 36, 3495-3497.	8.6	20
77	Substrate Compositional Variation with Tissue/Region and Gba1 Mutations in Mouse Models–Implications for Gaucher Disease. PLoS ONE, 2013, 8, e57560.	2.5	39
78	The estrogenic content of rodent diets, bedding, cages, and water bottles and its effect on bisphenol A studies. Journal of the American Association for Laboratory Animal Science, 2013, 52, 130-41.	1.2	50
79	Ex Vivo and in Vivo Effects of Isofagomine on Acid \hat{l}^2 -Glucosidase Variants and Substrate Levels in Gaucher Disease. Journal of Biological Chemistry, 2012, 287, 4275-4287.	3.4	97
80	Homozygosity mapping identifies a bile acid biosynthetic defect in an adult with cirrhosis of unknown etiology. Hepatology, 2012, 55, 1139-1145.	7.3	34
81	Novel Soy Germ Pasta Improves Endothelial Function, Blood Pressure, and Oxidative Stress in Patients With Type 2 Diabetes. Diabetes Care, 2011, 34, 1946-1948.	8.6	47
82	Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. American Journal of Clinical Nutrition, 2011, 94, 1284-1294.	4.7	93
83	Impact of perinatal exposure to equol enantiomers on reproductive development in rodents. Reproductive Toxicology, 2011, 32, 33-42.	2.9	13
84	Equol: History, Chemistry, and Formation. Journal of Nutrition, 2010, 140, 1355S-1362S.	2.9	398
85	Equol: Pharmacokinetics and Biological Actions ,. Journal of Nutrition, 2010, 140, 1363S-1368S.	2.9	155
86	The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis, 2010, 31, 886-893.	2.8	57
87	Analysis of Bile Acids. , 2010, , 837-966.		18
88	The Pharmacokinetics of S-(-)Equol Administered as SE5-OH Tablets to Healthy Postmenopausal Women ,. Journal of Nutrition, 2009, 139, 2037-2043.	2.9	58
89	Oral Cholic Acid for Hereditary Defects of Primary Bile Acid Synthesis: A Safe and Effective Long-term Therapy. Gastroenterology, 2009, 137, 1310-1320.e3.	1.3	91
90	A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. Age and Ageing, 2008, 38, 86-93.	1.6	82

#	Article	IF	CITATIONS
91	Pasta Naturally Enriched with Isoflavone Aglycons from Soy Germ Reduces Serum Lipids and Improves Markers of Cardiovascular Risk. Journal of Nutrition, 2007, 137, 2270-2278.	2.9	95
92	Disorders of Bile Acid Synthesis and Metabolism: A Metabolic Basis for Liver Disease., 2007,, 736-766.		10
93	Variations in Phytoestrogen Content between Different Mill Dates of the Same Diet Produces Significant Differences in the Time of Vaginal Opening in CD-1 Mice and F344 Rats but Not in CD Sprague-Dawley Rats. Environmental Health Perspectives, 2007, 115, 1717-1726.	6.0	60
94	Positive Benefits of Consuming Soyâ€Derived Isoflavones on Body Weight Gain and Cardiovascular Health Examined in an Ovariectomized Rat Model. FASEB Journal, 2007, 21, A694.	0.5	0
95	Guest Editorial: Assessing Risks and Benefits of Genistein and Soy. Environmental Health Perspectives, 2006, 114, A332-3.	6.0	17
96	Method of Defining Equol-Producer Status and Its Frequency among Vegetarians. Journal of Nutrition, 2006, 136, 2188-2193.	2.9	274
97	Factors Affecting the Bioavailability of Soy Isoflavones in Humans after Ingestion of Physiologically Relevant Levels from Different Soy Foods. Journal of Nutrition, 2006, 136, 45-51.	2.9	212
98	Defects in Bile Acid Biosynthesis-Diagnosis and Treatment. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, S17-S22.	1.8	114
99	S-Equol, a potent ligand for estrogen receptor \hat{l}^2 , is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora $1\hat{a}\in 4$. American Journal of Clinical Nutrition, 2005, 81, 1072-1079.	4.7	406
100	Pharmacokinetics of a Slow-Release Formulation of Soybean Isoflavones in Healthy Postmenopausal Women. Journal of Agricultural and Food Chemistry, 2005, 53, 1938-1944.	5.2	30
101	Equol Is a Novel Anti-Androgen that Inhibits Prostate Growth and Hormone Feedback 1. Biology of Reproduction, 2004, 70, 1188-1195.	2.7	201
102	Selecting the Appropriate Rodent Diet for Endocrine Disruptor Research and Testing Studies. ILAR Journal, 2004, 45, 401-416.	1.8	92
103	Bile acids analysis: a tool to assess graft function in human liver transplantation. Transplant International, 2004, 17, 286-292.	1.6	14
104	Soymilk or progesterone for prevention of bone loss. European Journal of Nutrition, 2004, 43, 246-257.	3.9	163
105	Liver disease caused by failure to racemize trihydroxycholestanoic acid: Gene mutation and effect of bile acid therapy. Gastroenterology, 2003, 124, 217-232.	1.3	145
106	Variations in Isoflavone Levels in Soy Foods and Soy Protein Isolates and Issues Related to Isoflavone Databases and Food Labeling. Journal of Agricultural and Food Chemistry, 2003, 51, 4146-4155.	5.2	141
107	Molecular Genetics of $3\hat{1}^2$ -Hydroxy- $\hat{1}$ "5-C27-Steroid Oxidoreductase Deficiency in 16 Patients with Loss of Bile Acid Synthesis and Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1833-1841.	3.6	96
108	Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. American Journal of Clinical Nutrition, 2003, 78, 593S-609S.	4.7	319

#	Article	IF	CITATIONS
109	Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. American Journal of Clinical Nutrition, 2003, 77, 411-419.	4.7	268
110	Bioavailability, Disposition, and Dose-Response Effects of Soy Isoflavones When Consumed by Healthy Women at Physiologically Typical Dietary Intakes. Journal of Nutrition, 2003, 133, 1027-1035.	2.9	256
111	Dietary phytoestrogens accelerate the time of vaginal opening in immature CD-1 mice. Comparative Medicine, 2003, 53, 607-15.	1.0	44
112	Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. American Journal of Clinical Nutrition, 2002, 76, 447-453.	4.7	516
113	The Clinical Importance of the Metabolite Equolâ€"A Clue to the Effectiveness of Soy and Its Isoflavones. Journal of Nutrition, 2002, 132, 3577-3584.	2.9	980
114	Soy Isoflavonesâ€"Benefits and Risks from Nature's Selective Estrogen Receptor Modulators (SERMs). Journal of the American College of Nutrition, 2001, 20, 354S-362S.	1.8	306
115	Bioavailability of Pure Isoflavones in Healthy Humans and Analysis of Commercial Soy Isoflavone Supplements. Journal of Nutrition, 2001, 131, 1362S-1375S.	2.9	837
116	Animal Models Impacted by Phytoestrogens in Commercial Chow: Implications for Pathways Influenced by Hormones. Laboratory Investigation, 2001, 81, 735-747.	3.7	263
117	Absorption and Metabolism of Soy Isoflavonesâ€"from Food to Dietary Supplements and Adults to Infants. Journal of Nutrition, 2000, 130, 654S-655S.	2.9	106
118	Dietary Isoflavones: Biological Effects and Relevance to Human Health. Journal of Nutrition, 1999, 129, 758S-767S.	2.9	927
119	Fetal and Neonatal Expression of the Apical Sodium-Dependent Bile Acid Transporter in the Rat Ileum and Kidney1. Pediatric Research, 1997, 42, 189-194.	2.3	49
120	Performance characteristics of reversed-phase bonded silica cartridges for serum bile acid extraction., 1996, 10, 1-5.		29
121	Performance characteristics of reversedâ€phase bonded silica cartridges for serum bile acid extraction. Biomedical Chromatography, 1996, 10, 1-5.	1.7	1
122	Biological effects of isoflavones in young women: importance of the chemical composition of soyabean products. British Journal of Nutrition, 1995, 74, 587-601.	2.3	262
123	Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture. Hepatology, 1995, 22, 82-87.	7.3	36
124	Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture. Hepatology, 1995, 22, 82-87.	7.3	2
125	Effects of Infant Nutrition on Cholesterol Synthesis Rates. Pediatric Research, 1994, 35, 135-140.	2.3	167
126	Metabolism and effect of 7-oxo-lithocholic acid 3-sulfate on bile flow and biliary lipid secretion in rats. Hepatology, 1994, 20, 663-671.	7.3	2

#	Article	IF	Citations
127	Soy intake and cancer risk: A review of the <i>in vitro </i> i>and <i>in vivo </i> data. Nutrition and Cancer, 1994, 21, 113-131.	2.0	1,294
128	Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (\mathring{l} "4-3-oxosteroid $5\mathring{l}^2$ -reductase deficiency). Hepatology, 1993, 18, 1096-1101.	7.3	85
129	Genistein, daidzein, and their .betaglycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. Journal of Agricultural and Food Chemistry, 1993, 41, 1961-1967.	5.2	810
130	Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (l "4-3-oxosteroid $5l$ ² -reductase deficiency). Hepatology, 1993, 18, 1096-1101.	7. 3	2
131	Oral bile acid treatment and the patient with zellweger syndrome. Hepatology, 1992, 15, 198-207.	7.3	102
132	Ursodeoxycholic acid therapy in cystic fibrosisâ€"associated liver disease: A dose-response study. Hepatology, 1992, 16, 924-930.	7.3	127
133	Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study. Hepatology, 1991, 13, 339-344.	7.3	95
134	Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: A study of bile acid metabolism. Hepatology, 1991, 13, 1076-1083.	7. 3	24
135	Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology, 1991, 14, 1000-1007.	7.3	122
136	Analysis of vitamin D and its metabolites using thermospray liquid chromatography/mass spectrometry. Biomedical Chromatography, 1991, 5, 153-160.	1.7	32
137	Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology, 1991, 14, 1000-1007.	7.3	12
138	Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study. Hepatology, 1991, 13, 339-344.	7.3	11
139	Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology, 1990, 12, 322-334.	7.3	78
140	Nutritional considerations in the pathogenesis of hepatic veno-occlusive disease in captive cheetahs. Zoo Biology, 1989, 8, 339-347.	1.2	19
141	Absence of an Acinar Gradient for Bile Acid Uptake in Developing Rat Liver. Pediatric Research, 1987, 21, 417-421.	2.3	17